He led the teams and was a clinical investigator on several successful NDAs, including nizatidine (H2-antagonist), pinacidil (K+ channel opener), and olanzapine (an atypical antipsychotic). He has experience developing drugs in the fields of cardiology, gastroenterology, psychiatry, pulmonary, rheumatology, infectious disease, diabetes, and opiate pharmacology.

Pharmacology, Toxicology
PhD, University of Minnesota, Pharmacology, 1982
MD, University of Kentucky, 1969
BA, Bellarmine College, 1965
BS, Marquette University, Biomedical Engineering